Key result
Lanatoside C reduces TET2-KD myeloid infiltration, cardiomyocyte apoptosis, and fibrosis in a preclinical SCO model.
Why the study?
Genome-wide association studies link CVD with CHIP, particularly TET2 mutations, prompting the need to determine whether self-organizing cardiac organoids can model cardiovascular CHIP and identify potential therapeutics.
Do selected drugs like Lanatoside C reduce inflammation and improve cardiac function in a TET2 cardiac-CHIP organoid model?
Population
Self-organizing cardiac organoids infiltrated with TET2-knockdown myeloid cells
Comparison
Selected drug treatments vs vehicle/drug control groups
Design
Pre-clinical in vitro engineered cardiac organoid study
Authors
Loading...
Should not change practice; extends TET2 organoid models for testing repurposed agents in CHIP.
Do selected drugs like Lanatoside C reduce inflammation and improve cardiac function in a TET2 cardiac-CHIP organoid model?
A novel TET2 cardiac-CHIP organoid model demonstrates that Lanatoside C can rescue CHIP-induced cardiac inflammation, fibrosis, and apoptosis, highlighting its potential for repurposing in CHIP-related cardiovascular disease.
Wang et al. (2025) studied TET2-mutant cardiovascular CHIP. Lanatoside C vs. Vehicle was evaluated on Inflammation, fibrosis, apoptosis, and cardiac contractile function. Treatment with Lanatoside C reduced myeloid cell infiltration, inflammation, fibrosis, and cardiomyocyte apoptosis in a self-organizing cardiac organoid model of TET2-mutant CHIP.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: